Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 15/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.46 |
| ▸ | TLR4 | O00206 | 2/20 | 0.46 |
| ▸ | TLR3 | O15455 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5806705 | 0.70 | MAPT (0.44) | — | |
| SCHEMBL5821898 | 0.69 | TLR9 (0.69) | TLR9TLR7CARM1TLR8TLR4 | |
| SCHEMBL5820765 | 0.69 | TLR9 (1.00) | TLR9TLR7CARM1TLR8TLR4 | |
| SCHEMBL5818484 | 0.69 | TLR9 (0.65) | TLR9TLR7CARM1TLR8TLR4 | |
| SCHEMBL4564057 | 0.68 | CARM1 (0.58) | TLR9TLR7CARM1PRMT6TLR8 | |
| SCHEMBL5821409 | 0.67 | TLR9 (1.00) | TLR9TLR7CARM1TLR8TLR4 | |
| SCHEMBL5823090 | 0.67 | TLR9 (0.83) | TLR9TLR7CARM1TLR8TLR4 | |
| SCHEMBL5067456 | 0.66 | TLR9 (0.53) | TLR9TLR7CARM1PRMT6TLR8 | |
| SCHEMBL5820154 | 0.66 | TLR9 (0.79) | TLR9TLR7CARM1TLR8TLR4 | |
| SCHEMBL5066966 | 0.66 | CARM1 (0.55) | TLR9TLR7CARM1PRMT6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006113458-A1 | HETEROCYCLIC INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | PRMT1, PRMT3, PRMT8 | TLR9 2751/4885TLR7 2861/4885CARM1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.